Walter Ageno to Aged
This is a "connection" page, showing publications Walter Ageno has written about Aged.
Connection Strength
0.169
-
Clinical risk scores for the early prediction of severe outcomes in patients hospitalized for COVID-19. Intern Emerg Med. 2021 06; 16(4):989-996.
Score: 0.017
-
Coagulation parameters and venous thromboembolism in patients with and without COVID-19 admitted to the Emergency Department for acute respiratory insufficiency. Thromb Res. 2020 12; 196:209-212.
Score: 0.016
-
Characteristics and Management of Patients with Venous Thromboembolism: The GARFIELD-VTE Registry. Thromb Haemost. 2019 Feb; 119(2):319-327.
Score: 0.014
-
Long-term recurrence of venous thromboembolism after short-term treatment of symptomatic isolated distal deep vein thrombosis: A cohort study. Vasc Med. 2017 12; 22(6):518-524.
Score: 0.013
-
Analysis of patients with deep vein thrombosis switched from standard therapy to rivaroxaban in the non-interventional XALIA study. Thromb Res. 2017 Jul; 155:23-27.
Score: 0.013
-
Incidence rates and case fatality rates of portal vein thrombosis and Budd-Chiari Syndrome. Thromb Haemost. 2017 04 03; 117(4):794-800.
Score: 0.013
-
Incidence of chronic thromboembolic pulmonary hypertension after a first episode of pulmonary embolism. Chest. 2006 Jul; 130(1):172-5.
Score: 0.006
-
Introduction of SARS-CoV-2 variant of concern 20h/501Y.V2 (B.1.351) from Malawi to Italy. Emerg Microbes Infect. 2021 Dec; 10(1):710-712.
Score: 0.004
-
Disentangling the Association of Hydroxychloroquine Treatment with Mortality in Covid-19 Hospitalized Patients through Hierarchical Clustering. J Healthc Eng. 2021; 2021:5556207.
Score: 0.004
-
Clinical factors associated with death in 3044 COVID-19 patients managed in internal medicine wards in Italy: results from the SIMI-COVID-19 study of the Italian Society of Internal Medicine (SIMI). Intern Emerg Med. 2021 Jun; 16(4):1005-1015.
Score: 0.004
-
Heparin in COVID-19 Patients Is Associated with Reduced In-Hospital Mortality: The Multicenter Italian CORIST Study. Thromb Haemost. 2021 Aug; 121(8):1054-1065.
Score: 0.004
-
Common cardiovascular risk factors and in-hospital mortality in 3,894 patients with COVID-19: survival analysis and machine learning-based findings from the multicentre Italian CORIST Study. Nutr Metab Cardiovasc Dis. 2020 10 30; 30(11):1899-1913.
Score: 0.004
-
Accuracy of age-adjusted D-dimer to rule out deep vein thrombosis in the elderly. Thromb Res. 2019 02; 174:148-150.
Score: 0.004
-
Healthcare resource use in XALIA: A subgroup analysis of a non-interventional study of rivaroxaban versus standard anticoagulation for deep vein thrombosis. Eur J Intern Med. 2019 03; 61:29-33.
Score: 0.004
-
Risk of bleeding and arterial cardiovascular events in patients with splanchnic vein thrombosis in Denmark: a population-based cohort study. Lancet Haematol. 2018 Oct; 5(10):e441-e449.
Score: 0.003
-
Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness. N Engl J Med. 2018 Sep 20; 379(12):1118-1127.
Score: 0.003
-
Long-Term Outcome of Splanchnic Vein Thrombosis in Cirrhosis. Clin Transl Gastroenterol. 2018 08 15; 9(8):176.
Score: 0.003
-
Biomarkers for the diagnosis of venous thromboembolism: D-dimer, thrombin generation, procoagulant phospholipid and soluble P-selectin. J Clin Pathol. 2018 Nov; 71(11):1015-1022.
Score: 0.003
-
Management of major bleeding and outcomes in patients treated with direct oral anticoagulants: results from the START-Event registry. Intern Emerg Med. 2018 Oct; 13(7):1051-1058.
Score: 0.003
-
Cancer-associated ischemic stroke: A retrospective multicentre cohort study. Thromb Res. 2018 05; 165:33-37.
Score: 0.003
-
European Guidelines on perioperative venous thromboembolism prophylaxis: Executive summary. Eur J Anaesthesiol. 2018 02; 35(2):77-83.
Score: 0.003
-
Impact of age, comorbidity, and polypharmacy on the efficacy and safety of edoxaban for the treatment of venous thromboembolism: An analysis of the randomized, double-blind Hokusai-VTE trial. Thromb Res. 2018 02; 162:7-14.
Score: 0.003
-
Outpatient Management in Patients with Venous Thromboembolism with Edoxaban: A Post Hoc Analysis of the Hokusai-VTE Study. Thromb Haemost. 2017 12; 117(12):2406-2414.
Score: 0.003
-
Pulmonary embolism prognostic factors and length of hospital stay: A cohort study. Thromb Res. 2017 Aug; 156:155-159.
Score: 0.003
-
Impact of residual pulmonary obstruction on the long-term outcome of patients with pulmonary embolism. Eur Respir J. 2017 05; 49(5).
Score: 0.003
-
Recanalization rate in patients with proximal vein thrombosis treated with the direct oral anticoagulants. Thromb Res. 2017 May; 153:97-100.
Score: 0.003
-
Managing challenging patients with venous thromboembolism: a practical, case-based approach. Pol Arch Intern Med. 2017 Jan 04; 127(1):41-46.
Score: 0.003
-
Time trends and case fatality rate of in-hospital treated pulmonary embolism during 11 years of observation in Northwestern Italy. Thromb Haemost. 2016 Jan; 115(2):399-405.
Score: 0.003
-
In-hospital mortality for pulmonary embolism: relationship with chronic kidney disease and end-stage renal disease. The hospital admission and discharge database of the Emilia Romagna region of Italy. Intern Emerg Med. 2013 Dec; 8(8):735-40.
Score: 0.002
-
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med. 2008 Jun 26; 358(26):2776-86.
Score: 0.002